Clinical Trial Update: Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity and safety of Menactra vaccine in children aged 9 to 23 months in India and Russia; study completed with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Infection

Drugs mentioned

• Menactra (Meningococcal conjugate vaccine (A, C, W, Y))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningitis, Meningococcal Infection | Phase 3 | Status: COMPLETED | Results posted: 2017-08-21